Yazan Hamadneh

Dr. Yazan Hamadneh

School of Medicine, University of Jordan, Amman, Al ‘Āşimah, Jordan
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2022 in Frontiers in Public Health
Verified
Journal Article
Open access
AAAnas Haider Abu-Humaidan
Anas Haider Abu-Humaidan
ATAlaa Tarazi
Alaa Tarazi
YHYazan Hamadneh
Yazan Hamadneh
AAAhmad Al-Leimon
Ahmad Al-Leimon
OAObada Nayef Al-leimon
Obada Nayef Al-leimon
NANader Alaridah
Nader Alaridah
Background: Tuberculosis (TB) is one of the leading causes of death from infectious diseases worldwide with numerous undiagnosed and untreated cases, emphasizing the need for TB awareness to minimize transmission and initiate early treatment. Data regarding the knowledge, attitudes, and practices (KAP) toward TB among Jordanians is lacking but requires attention given the massive migration spells to Jordan from neighboring countries in the past decade.Methods: A descriptive cross-sectional study was conducted from May to June 2022. An online questionnaire was developed following World Health Organization (WHO) recommendations for TB KAP surveys and was distributed to Jordanian university students. The questionnaire documented sociodemographic data and measured participants' KAP toward TB. Descriptive and analytic statistics were used to report KAP levels and highlight relevant sociodemographic factors associated with better KAP.Results: 602 participants completed the survey; most were females (60.8%), in their first 3 years of school (84.4%), and from a healthcare field of study (57.0%). The knowledge section median score was 27 out of 51. Knowledge gaps in TB treatment, and to a lesser extent, TB transmission routes were identified. The attitudes section median score was 6 out of 9, attitudes were generally positive toward TB patients with no indication of a social stigma. The practice section median score was 6 out of 8, most participants would take the correct measures if they suspected being infected, yet around 41.0% were not confident that masks are important in preventing airborne diseases. Students in healthcare specialties had significantly better KAP scores and identifying as a smoker was associated with a lower practice score.Conclusion: Although university students displayed satisfactory KAP scores, the focus should be aimed at informing students from non-healthcare fields on TB transmission routes, treatment options, and the role of masks in preventing disease transmission.

AAAnas Haider Abu-Humaidan
Anas Haider Abu-Humaidan
JAJawad Alrawabdeh
Jawad Alrawabdeh
LTLaith S Theeb
Laith S Theeb
YHYazan Hamadneh
Yazan Hamadneh
MOMohammad B Omari
Mohammad B Omari
Human microbiota have a significant impact on the health of individuals, and reciprocally, lifestyle choices of individuals have an important effect on the diversity and composition of microbiota. Studies assessing microbiota knowledge among the public are lacking, although it is hypothesized that this knowledge can motivate healthier behavior. Hence, this study aimed to measure microbiota knowledge among university students, and the effect of this knowledge on behavioral beliefs. A descriptive cross-sectional study was conducted among students from various fields of study enrolled at the University of Jordan, using an online questionnaire. The questionnaire consisted of 3 parts: demographics, general knowledge of microbiota, and behavioral beliefs related to microbiota. Four hundred and two responses were collected from verified university students. Participants were divided into two groups depending on whether they took a formal microbiology course (45 h) or not. Results from those two groups were compared using appropriate statistical methods. Results showed that most participants, even those who did not take a formal microbiology course, displayed good knowledge of what microbiota is and how they can be influenced by personal and environmental factors. Participants who took a microbiology course had significantly higher microbiota knowledge scores and were more aware of the effect of antibiotics on microbiota. Participants’ behavioral beliefs regarding their antibiotic use, but not their diet and lifestyle choices, were affected by their knowledge of microbiota. The study indicates that disseminating knowledge regarding microbiota and microbiology in general, can improve behaviors related to antibiotic use.

20 February 2023 in Tissue Engineering and Regenerative Medicine
Verified
Journal Article
Closed access
PDF file
DADuaa Abuarqoub
Duaa Abuarqoub
LTLaith S. Theeb
Laith S. Theeb
MOMohammad B. Omari
Mohammad B. Omari
YHYazan Hamadneh
Yazan Hamadneh
JAJawad A. Alrawabdeh
Jawad A. Alrawabdeh
AAAbdalla Awidi
Abdalla Awidi

13 July 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MAMarah Alzu’bi
Marah Alzu’bi
HBHisham Bawa’neh
Hisham Bawa’neh
AAAlaa Alshorman
Alaa Alshorman
JAJawad Alrawabdeh
Jawad Alrawabdeh
NONada Odeh
Nada Odeh
AAAbdalla Awidi
Abdalla Awidi
Reticulocyte hemoglobin (CHr) is a measure of the amount of hemoglobin in reticulocytes and a marker of cell hemoglobinization. In this study, we aimed to find the optimal cut-off point for reticulocyte hemoglobin to diagnose iron deficiency anemia using multiple methods. A total of 309 patients were included. The median age at diagnosis was 54 years. Most were females (71.2%). 68% had iron deficiency anemia. Patients with IDA had significantly lower levels of CHr compared to those who had non-IDA (p < 0.0001). The optimal cut-off value of CHr for detecting IDA, determined using various methods, was 30.15 pg. This cut-off point had a sensitivity of 87.8% and a specificity of 77.7%. CHr showed a significant positive correlation with hemoglobin, mean corpuscular volume, serum iron, serum ferritin, and transferrin saturation and a significant negative correlation with total iron-binding capacity. CHr levels correlate with most established laboratory tests for IDA. It reliably detects IDA. Our results indicate the importance of CHr in diagnosing IDA, and that CHr should be used more widely in suspected cases of IDA since it is a cheap, fast, and reliable test.

21 November 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Abdullah EsmailAbdullah Esmail
Abdullah Esmail
YHYazan Hamadneh
Yazan Hamadneh
BKBayan Khasawneh
Bayan Khasawneh
MAMaryam Al-Rawi
Maryam Al-Rawi
EAEbtesam Al-Najjar
Ebtesam Al-Najjar
Maen AbdelrahimMaen Abdelrahim
Maen Abdelrahim
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. Atezolizumab plus bevacizumab (Atezo/Bev) has emerged as a first-line therapy for unresectable HCC (uHCC), improving overall and progression-free survival (OS, overall survival and PFS, progression-free survival) in IMbrave150. This study evaluates the real-world efficacy and safety of Atezo/Bev in uHCC. Methods: A retrospective analysis was performed on 87 patients (median age 68 years) treated with Atezo/Bev at Houston Methodist Hospital between January 2020 and June 2023. Demographics, treatment patterns, radiological response, OS, PFS, and toxicities were reviewed. Atezo/Bev was administered per FDA guidelines (atezolizumab 1200 mg plus bevacizumab 15 mg/kg every 3 weeks). Results: Of 87 patients, 78% were male, 71% White, and 70% had BCLC stage C disease. Most (60%) had Child–Pugh class A liver function, and 62% had viral hepatitis. Median OS was 15.1 months (95% CI: 10.57–25.97) and PFS was 9.1 months (95% CI: 7.4–21.07). Objective response rate was 31.3% (CR 7.2%, PR 25%, SD 52%, PD 16%). OS was longer in CP A versus CP B patients (21.2 vs. 5.2 months, p < 0.001) and in those receiving post-Atezo/Bev locoregional therapy (21.2 vs. 10.4 months, p = 0.043). Discontinuation due to toxicity occurred in 14%, mainly gastrointestinal bleeding and fatigue. Conclusions: Atezo/Bev demonstrated favorable real-world efficacy and manageable toxicity in uHCC, particularly in patients with preserved liver function or multimodal therapy.

20 September 2022 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
JAJawad Alrawabdeh
Jawad Alrawabdeh
MAMarah Alzu'BI
Marah Alzu'BI
YHYazan Hamadneh
Yazan Hamadneh
NONada Odeh
Nada Odeh
MAMontaser Alzyoud
Montaser Alzyoud
HBHisham Bawa'NEh
Hisham Bawa'NEh